


PROTAC CDK9 degrader-6

Cat. No.:	HY-149963
CAS No.:	2935587-91-8
Molecular Formula:	C ₄₂ H ₄₉ Cl ₂ N ₉ O ₈
Molecular Weight:	878.8
Target:	CDK
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PROTAC CDK9 degrader-6 is a PROTAC targeting to CDK9 specifically. PROTAC CDK9 degrader-6 mediates CDK9 degradation via the proteasome. PROTAC CDK9 degrader-6 degrades CDK9 with DC ₅₀ s of 0.10 μM and 0.14 μM for the CDK9 ₄₂ and CDK9 ₅₅ isoforms, respectively ^[1] .									
IC₅₀ & Target	CDK9 ₄₂ 0.03 μM (DC50)	CDK9 ₅₅ 0.05 μM (DC50)								
In Vitro	<p>PROTAC CDK9 degrader-6 (compound 16) (1 μM; 6 h) decreases the protein level of MCL2, and completely degrades CDK9 in MV411 cells^[1].</p> <p>PROTAC CDK9 degrader-6 (1 μM; 1-6 h) time-dependently decreases the protein level of MCL2, and CDK9, and remains suppression for 24 h^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MV411 cells</td> </tr> <tr> <td>Concentration:</td> <td>1 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>1 h, 2 h, 4 h, 6 h</td> </tr> <tr> <td>Result:</td> <td>Degraded CDK9 starting at 2 h incubation and reaching a plateau at 4 h. Remained suppressed for 24 h with some recurrence at 48 h after finished treatment.</td> </tr> </table>		Cell Line:	MV411 cells	Concentration:	1 μM	Incubation Time:	1 h, 2 h, 4 h, 6 h	Result:	Degraded CDK9 starting at 2 h incubation and reaching a plateau at 4 h. Remained suppressed for 24 h with some recurrence at 48 h after finished treatment.
Cell Line:	MV411 cells									
Concentration:	1 μM									
Incubation Time:	1 h, 2 h, 4 h, 6 h									
Result:	Degraded CDK9 starting at 2 h incubation and reaching a plateau at 4 h. Remained suppressed for 24 h with some recurrence at 48 h after finished treatment.									

REFERENCES

[1]. Tokarski RJ 2nd, et al. Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation. Eur J Med Chem. 2023 Jun 5;254:115342.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA